RxDoctor Payments Data

David Wilt, MD

Internal Medicine · Kansas City, MONPI 1508857509

Payments from drug & device makers

$13,083in general payments, 2019–2025

Across 768 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Pfizer$544
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$13,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)91$1,484
AstraZeneca(2 entities)64$1,410
Novo Nordisk93$1,319
Amgen76$1,216
Lilly USA, LLC66$1,125
Pfizer41$544
Amarin Pharma, Inc.33$530
Sanofi-aventis U.S. LLC29$450
Johnson & Johnson(2 entities)24$402
Merck25$357
Eisai Inc.17$291
Bayer15$265
Dexcom, Inc.9$232
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$228
Xeris Pharmaceuticals, Inc.8$160
Boehringer Ingelheim7$158
Astellas Pharma US Inc8$150
Biohaven Pharmaceuticals, Inc.9$149
Nestle Healthcare Nutrition Inc.6$149
Novartis10$144
Kowa Pharmaceuticals America, Inc.11$143
Biogen7$142
IBSA Pharma Inc.7$112
Ultragenyx Pharmaceutical Inc.6$112
Biohaven Pharmaceutical Holding Company Ltd.6$111
Alnylam Pharmaceuticals Inc.6$109
Idorsia Pharmaceuticals US Inc5$108
Daiichi Sankyo Inc.5$105
Radius Health, Inc.3$97
Exact Sciences6$92
Kyowa Kirin, Inc.4$86
Ipsen Biopharmaceuticals, Inc3$79
EMD Serono, Inc.3$73
Mannkind Corporation4$70
Takeda Pharmaceuticals U.S.A., Inc.4$70
Acadia Pharmaceuticals Inc4$65
Lifescan, Inc.3$55
Amneal Pharmaceuticals LLC2$54
GSK3$49
MDD US Operations, LLC2$47
Cequr Corporation1$44
Antares Pharma, Inc.2$34
Amryt Pharma Holdings Ltd2$33
Esperion Therapeutics, Inc.2$32
E.r. Squibb & Sons, L.L.C.2$32
Tolmar, Inc.2$28
Corium, LLC1$25
Axsome Therapeutics, Inc.1$24
Verity Pharmaceuticals Inc.1$24
Averitas Pharma Inc.1$24
Gilead1$23
Sumitomo Pharma America, Inc.1$23
Ascendis Pharma Endocrinology Inc1$22
VBI Vaccine (delaware) Inc.1$22
Clarus Therapeutics Inc.1$20
Corcept Therapeutics1$20
Tersera Therapeutics LLC1$19
Recordati_rare_diseases_inc.1$17
Chiesi USA, Inc.1$17
Arbor Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,083 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$117,433
Medicare patients
366
Services billed
4,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$111,874
JardianceEmpagliflozin95$93,603
EliquisApixaban102$91,722
FarxigaDapagliflozin Propanediol83$74,714
JanuviaSitagliptin Phosphate57$72,128
OzempicSemaglutide45$60,412
XareltoRivaroxaban64$56,897
RybelsusSemaglutide30$42,052
MyrbetriqMirabegron62$34,683
VraylarCariprazine Hcl22$30,986
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$24,231
TrulicityDulaglutide13$21,429
EntrestoSacubitril/Valsartan15$17,415
Repatha SureclickEvolocumab14$16,858
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$14,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,125$133,303109 claims
Novo NordiskOzempic, Rybelsus$1,319$102,46475 claims
Boehringer IngelheimJardiance$158$93,60395 claims
PfizerEliquis$544$91,722102 claims
AstraZenecaFarxiga$1,410$74,71483 claims
MerckJanuvia$357$72,12857 claims
Johnson & JohnsonXarelto$402$56,89764 claims
AbbVieVraylar, Linzess, Synthroid$1,484$46,09290 claims
Astellas Pharma US IncMyrbetriq$150$34,68362 claims
GSKTrelegy Ellipta, Arexvy$49$33,15065 claims
NovartisEntresto$144$17,41515 claims
Kowa Pharmaceuticals America, Inc.Livalo$143$9,28917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →